DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN ASPART RECOMBINANT

« Back to Dashboard

Clinical Trials for Insulin Aspart Recombinant

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00046150	12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.	Completed	Sanofi	Phase 3	The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs.
NCT00065130	Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes	Completed	Novo Nordisk A/S	Phase 3	This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
NCT00071448	Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population	Completed	Novo Nordisk A/S	Phase 3	This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
NCT00082407	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	Eli Lilly and Company	Phase 3	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).

Clinical Trial Conditions for Insulin Aspart Recombinant

Condition Name

Condition Name for Insulin Aspart Recombinant
Intervention	Trials
Diabetes	251
Diabetes Mellitus, Type 2	157
Diabetes Mellitus, Type 1	118
Healthy	23

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Insulin Aspart Recombinant
Intervention	Trials
Diabetes Mellitus	310
Diabetes Mellitus, Type 2	190
Diabetes Mellitus, Type 1	151
Hyperglycemia	7

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Insulin Aspart Recombinant

Trials by Country

Trials by Country for Insulin Aspart Recombinant
Location	Trials
United States	922
Germany	79
India	54
China	51
Denmark	36

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Insulin Aspart Recombinant
Location	Trials
California	56
Texas	53
Florida	46
Georgia	40
New York	39

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Insulin Aspart Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Aspart Recombinant
Clinical Trial Phase	Trials
Phase 4	109
Phase 3	94
Phase 2/Phase 3	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Insulin Aspart Recombinant
Clinical Trial Phase	Trials
Completed	293
Recruiting	32
Unknown status	12

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Insulin Aspart Recombinant

Sponsor Name

Sponsor Name for Insulin Aspart Recombinant
Sponsor	Trials
Novo Nordisk A/S	271
Sanofi	16
Eli Lilly and Company	8

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Insulin Aspart Recombinant
Sponsor	Trials
Industry	331
Other	133
U.S. Fed	3

Export unavailable in trial.
Subscribe for complete access.